More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
Your search for major depressive disorder returned 47 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
With little being known about the predictors or moderators of dTMS outcome for OCD, this study sought to examine if several theoretically relevant variables may predict and moderate treatment effects including OCD symptom severity, functional impairment, co-occurring depressive symptoms, age, gender, age of OCD onset, and family history of OCD.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
While statins have both good and bad outcomes in the realm of neuropsychiatry, researchers looked at the possible associations with statins and suicidality, depression, anxiety, and seizures.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.
Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.
Study findings do not support the use of vitamin D3 supplementation to prevent depression in adults.
The use of genetic evaluation for suicidal ideation may represent a future application for precision medicine.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.
Children who receive a depression diagnosis in their primary school age have a substantially higher risk of a depression relapse during adolescence compared with children who did not receive a depression diagnosis during their primary school age.
Heightened cognitive arousal at bedtime is linked to objective sleep disturbances and indicators of psychological hyperarousal at night and during the day.
Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.
Can mere light become a revolutionary new treatment for traumatic brain injury, posttraumatic stress disorder, depression, stroke, Parkinson disease, and Alzheimer disease?
The study compared improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging in patients with TRD receiving rTMS treatment.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.
Responses to treatment depend on the target chosen, with 5 targets yielding positive outcomes, including the ventral anterior limb of the internal capsule, subthalamic nucleus, nucleus accumbens, ventral capsule/ventral striatum, or inferior thalamic peduncle, all involving fronto-striato-thalamocortical circuits.
The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.
Researchers sought to address the possible link between cognitive or mood symptoms and statins.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
This newly established center at Johns Hopkins is reinvigorating research on the potential therapeutic applications of psychedelics.
Latest News Your top articles for TuesdayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses